이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bonesupport Holding 관리

관리 기준 확인 4/4

Bonesupport Holding's CEO는 Emil Billbäck, Mar2018 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 SEK 15.18M, 41.7% 로 구성됩니다. 41.7% 급여 및 58.3% 보너스(회사 주식 및 옵션 포함). 는 SEK 112.52M 가치에 해당하는 회사 주식의 0.69% 직접 소유합니다. 112.52M. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 7.4 년입니다.

주요 정보

Emil Billbäck

최고 경영자

SEK 15.2m

총 보상

CEO 급여 비율	41.7%
CEO 임기	6.3yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	7.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Emil Billbäck 의 보수는 Bonesupport Holding 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	SEK 267m
Dec 31 2023	SEK 15m	SEK 6m	SEK 245m
Sep 30 2023	n/a	n/a	SEK 214m
Jun 30 2023	n/a	n/a	-SEK 30m
Mar 31 2023	n/a	n/a	-SEK 51m
Dec 31 2022	SEK 18m	SEK 5m	-SEK 68m
Sep 30 2022	n/a	n/a	-SEK 72m
Jun 30 2022	n/a	n/a	-SEK 71m
Mar 31 2022	n/a	n/a	-SEK 82m
Dec 31 2021	SEK 6m	SEK 4m	-SEK 86m
Sep 30 2021	n/a	n/a	-SEK 88m
Jun 30 2021	n/a	n/a	-SEK 96m
Mar 31 2021	n/a	n/a	-SEK 92m
Dec 31 2020	SEK 11m	SEK 6m	-SEK 101m
Sep 30 2020	n/a	n/a	-SEK 115m
Jun 30 2020	n/a	n/a	-SEK 127m
Mar 31 2020	n/a	n/a	-SEK 151m
Dec 31 2019	SEK 8m	SEK 5m	-SEK 161m
Sep 30 2019	n/a	n/a	-SEK 166m
Jun 30 2019	n/a	n/a	-SEK 191m
Mar 31 2019	n/a	n/a	-SEK 182m
Dec 31 2018	SEK 6m	SEK 4m	-SEK 176m

보상 대 시장: Emil 의 총 보상 ($USD 1.46M ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.38M ).

보상과 수익: Emil 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Emil Billbäck (54 yo)

6.3yrs

테뉴어

SEK 15,176,000

보상

Mr. Emil Billbäck serves as Director of Intervacc AB (publ) since May 15, 2024. He has been Chief Executive Officer at BONESUPPORT HOLDING AB (publ) since March 01, 2018. Mr. Billbäck is the Chief Executiv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Emil Billbäck	Chief Executive Officer	6.3yrs	SEK 15.18m	0.69% SEK 121.1m
Håkan Johansson	Chief Financial Officer	5.6yrs	SEK 248.00k	0.084% SEK 14.7m
Michael Mortensen	Executive Vice President of Global R&D and Operations	2.5yrs	데이터 없음	0% SEK 0
Annelie Vikner	Executive Vice President of Global Marketing	1.4yrs	데이터 없음	0.022% SEK 3.9m
Helena Brandt	Executive Vice President of Human Resources	6.7yrs	데이터 없음	0.015% SEK 2.7m
Michael Diefenbeck	Executive VP of Medical & Clinical Affairs and Chief Medical Officer	7.2yrs	데이터 없음	0.10% SEK 17.4m
Fergus MacLeod	GM & Executive VP of Commercial Operations of EUROW	4.6yrs	데이터 없음	0.036% SEK 6.4m
Michael Roth	GM & Executive VP of Commercial Operations of North America	4yrs	데이터 없음	0.030% SEK 5.3m

5.1yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: BONEXS 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Björn Odlander	Director	14.4yrs	SEK 302.00k	데이터 없음
Lennart Johansson	Independent Chairman of the Board	7.4yrs	SEK 2.94m	0.16% SEK 28.2m
Sven Bjorklund	Independent Director	7.5yrs	SEK 253.00k	데이터 없음
Christine Rankin	Independent Director	2.1yrs	SEK 756.00k	0.0030% SEK 523.9k
Mary O'Connor	Independent Director	2.1yrs	SEK 515.00k	0.038% SEK 6.6m

7.4yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: BONEXS 의 이사회는 경험(평균 재직 기간 7.4 년)으로 간주됩니다.

Bonesupport Holding 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Insider recently bought kr426k worth of stock

Insider recently sold kr701k worth of stock

Chief Executive Officer recently sold kr15m worth of stock

No independent directors

Recent updates

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

No independent directors

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

No independent directors

No independent directors

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

No independent directors

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

No independent directors

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

No independent directors

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Less than half of directors are independent

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings released

Forecast to breakeven in 2023

Less than half of directors are independent

Bonesupport Announces Supplementary US Denovo Application Submitted

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Less than half of directors are independent

Executive VP of R&D recently sold kr595k worth of stock

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Bonesupport Holding AB (publ) Receives Notification from the US Food and Drug Administration

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Revenue beats expectations

Executive VP of R&D recently bought kr69k worth of stock

Executive VP of R&D recently bought kr69k worth of stock

New 90-day high: kr77.00

New 90-day high: kr75.60

Bonesupport Holding AB (Publ) Announces Resignation of Simon Cartmell from the Board of Directors

Bonesupport Holding AB (publ) to Report First Half, 2021 Results on Jul 15, 2021

CEO 보상 분석

CEO